Not finding it? Sign in to also search OpenAlex live.
-
Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, Tobias A.W. Holderried, Jochen J. Frietsch, Stefan Klein, +18 more
0citations -
P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Romain Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +18 more
1citations -
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT2023 Bone Marrow Transplantation article Medicine Multiple Myeloma Research and Treatments Open access
Rémi Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +20 more
2citations -
Long-Term Comparative Outcomes in Relapse Activity and Disability Progression Among Anti-CD20 Therapies in Relapsing Multiple Sclerosis: An Unanchored Matching-Adjusted Indirect Comparison2026 Multiple Sclerosis and Related Disorders article Medicine Multiple Sclerosis Research Studies Open access
Ralf Gold, Amir Ansaripour, Klaus Schmierer, Michael Barnett, Hans Peter Hartung, Yamout Bassem, +8 more
0citations -
Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter
Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, +4 more
2citations -
POS1173 LONG-TERM ANALYSIS OF RELAPSE RATES IN A EUROPEAN ANCA-ASSOCIATED VASCULITIS (AAV) COHORT FOR GPA AND MPA2023 Annals of the Rheumatic Diseases conference-abstract Medicine Vasculitis and related conditions Open access
Stefan Krämer, Thomas Rauen, K. Pruin, Teresa M Anslinger, Martin Busch, Raoul Bergner, +1 more
2citations -
P18.02.B ANALYSIS OF TUMOR RELAPSE PROBABILITY AND OVERALL SURVIVAL PREDICTION FOLLOWING CONCOMITANT RADIOTHERAPY WITH TEMOZOLOMIDE USING FET PET IN PATIENTS WITH GLIOBLASTOMA
Isabelle Stetter, Jan‐Michael Werner, Michael Wollring, Garry S. Ceccon, Philipp Lohmann, Gabriele Stoffels, +4 more
0citations -
NIMG-42. ANALYSIS OF TUMOR RELAPSE PROBABILITY AND OVERALL SURVIVAL PREDICTION FOLLOWING TEMOZOLOMIDE CHEMORADIATION USING FET PET INCLUDING RADIOMICS IN PATIENTS WITH GLIOBLASTOMA
Isabelle Stetter, Jan‐Michael Werner, Michael Wollring, Garry S. Ceccon, Philipp Lohmann, Keith George Ciantar, +5 more
0citations -
Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA2022 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Frederik Marmé, Marcus Schmidt, Jenny Furlanetto, Carsten Denkert, Anthony Gonçalvès, Elmar Stickeler, +15 more
0citations -
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
Frederik Marmé, Elmar Stickeler, Jenny Furlanetto, Carsten Denkert, Marcus Schmidt, Mattea Reinisch, +10 more
27citations -
Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)
Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg‐Nikolaus Franke, +10 more
0citations -
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Krämer, Bertram Glaß, +21 more
2citations -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
Andreas Burchert, Susanne Saußele, Christian Jean Michel, Stephan Metzelder, Andreas Hochhaus, Norbert Gattermann, +28 more
13citations -
Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation2024 Transplantation and Cellular Therapy article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nico Gagelmann, Claudia Schuh, Robert Zeiser, Matthias Stelljes, Wolfgang Andreas Bethge, Gerald Georg Wulf, +7 more
10citations